Jazz Earnings: Strong Uptake of Xywav and Epidiolex Drive Sales; Shares Undervalued

Jazz Pharmaceuticals reported third-quarter results highlighted by total revenue of $972 million, representing a 3% increase from the prior-year period. Xywav, which is the low-sodium version of Xyrem for the treatment of cataplexy and excessive daytime sleepiness, has continued to see strong patient uptake, and sales grew 30% year over year. Over 12,000 patients are actively taking the medicine at the end of the third quarter, up from 9,500 at the same time last year.